Description

Elpamotide is an epitope peptide derived from VEGFR2. Elpamotide induces cytotoxic T lymphocytes (CTLs) to kill VEGFR2-expressing endothelial cells. Elpamotide has potential immunostimulatory and antineoplastic activities. Elpamotide can be used in the research of cancer, such as pancreatic cancer[1][2].—Cancer-programmed cell death–C47H76N16O13—-[1]Yamaue H, et al. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Cancer Sci. 2015 Jul;106(7):883-90. |[2]Wada S, et al. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005 Jun 1;65(11):4939-46. –673478-49-4–1073.21—-N=C(N)NCCC[C@H](N)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](C(C)C)C(N2[C@@H](CCC2)C(N[C@@H](CC(O)=O)C(NCC(N[C@@H](CC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(O)=O)[C@@H](C)CC)=O)=O)=O)=O)=O)=O)=O)=O–Cancer–10 mM in DMSO–Others—-Others–Peptides